Cargando…

The impact of Host vs. Graft mismatches on rejection of haploidentical bone marrow transplants in thalassemia patients using posttransplant cyclophosphamide

Detalles Bibliográficos
Autores principales:	Marwah, Priya, Soni, Rajpreet, Ramprakash, Stalin, Raghuram, C. P., Trivedi, Deepa, Kumar Agarwal, Rajat, Dhanya, Rakesh, Sedai, Amit, Kumari, Ankita, Parmar, Lalith, Faulkner, Lawrence
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452814/ https://www.ncbi.nlm.nih.gov/pubmed/31570780 http://dx.doi.org/10.1038/s41409-019-0692-0

Ejemplares similares

Rejection of paternal vs maternal fully matched bone marrow grafts in children with thalassemia
por: Ramprakash, S, et al.
Publicado: (2017)

Information Technology–Assisted Treatment Planning and Performance Assessment for Severe Thalassemia Care in Low- and Middle-Income Countries: Observational Study
por: Agarwal, Rajat Kumar, et al.
Publicado: (2019)

New‐onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide
por: Mangan, Brendan L., et al.
Publicado: (2020)

HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide
por: Bacigalupo, Andrea, et al.
Publicado: (2016)

Haploidentical Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide for Sézary Syndrome
por: Kanda-Kato, Madoka, et al.
Publicado: (2020)

Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide
por: Al Malki, Monzr M., et al.
Publicado: (2022)

Haploidentical bone marrow transplant with posttransplant cyclophosphamide for sickle cell disease: An update
por: Patel, Dilan A., et al.
Publicado: (2020)

Setting up and sustaining blood and marrow transplant services for children in middle-income economies: an experience-driven position paper on behalf of the EBMT PDWP
por: Faulkner, Lawrence, et al.
Publicado: (2020)

Myeloablative Conditioning with PBSC Grafts for T Cell-Replete Haploidentical Donor Transplantation Using Posttransplant Cyclophosphamide
por: Solomon, Scott R., et al.
Publicado: (2016)

Progressive substitution of posttransplant cyclophosphamide with bendamustine: A phase I study in haploidentical bone marrow transplantation
por: Katsanis, Emmanuel, et al.
Publicado: (2020)

Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide
por: Mariotti, Jacopo, et al.
Publicado: (2019)

Haploidentical hematopoietic stem cell transplantation with one-day posttransplant cyclophosphamide and anti-thymocyte globulin for graft failure
por: Imanaga, Hiroshi, et al.
Publicado: (2020)

Haploidentical transplant with posttransplant cyclophosphamide vs matched related and unrelated donor transplant in acute myeloid leukemia and myelodysplastic neoplasm
por: Rieger, Max J., et al.
Publicado: (2023)

Is it safe and efficacious to remove central lines in pediatric bone marrow transplant patients with platelets less than 20,000/μl?
por: Marwah, Priya, et al.
Publicado: (2022)

Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft‐versus‐host disease prophylaxis
por: Hernani, Rafael, et al.
Publicado: (2021)

Case report: HLA-haploidentical hematopoietic cell transplant with posttransplant cyclophosphamide in a patient with leukocyte adhesion deficiency type I
por: Yamashita, Motoi, et al.
Publicado: (2022)

A study of the noncompliance of blood banks on safety and quality parameters in blood donation camps in Bengaluru
por: Agarwal, Rajat Kumar, et al.
Publicado: (2015)

Complications related to blood donation: A multicenter study of the prevalence and influencing factors in voluntary blood donation camps in Karnataka, India
por: Agarwal, Rajat Kumar, et al.
Publicado: (2016)

Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant
por: Jimenez Jimenez, Antonio, et al.
Publicado: (2022)

Idiopathic Pneumonia Syndrome and Thrombotic Microangiopathy Following Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation and Posttransplant Cyclophosphamide: A Case Report
por: Liu, Wei-Hsin, et al.
Publicado: (2015)

Total body irradiation-based haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide after administration of inotuzumab ozogamicin: A case report
por: Abe, Masaya, et al.
Publicado: (2021)

The Benefits of the Post-Transplant Cyclophosphamide in Both Haploidentical and Mismatched Unrelated Donor Setting in Allogeneic Stem Cells Transplantation
por: Dybko, Jarosław, et al.
Publicado: (2023)

Mild Acute Graft-Versus-Host Disease Improves Outcomes After HLA-Haploidentical-Related Donor Transplantation Using Posttransplant Cyclophosphamide and Cord Blood Transplantation
por: Wada, Fumiya, et al.
Publicado: (2023)

Choice of Unmanipulated T Cell Replete Graft for Haploidentical Stem Cell Transplant and Posttransplant Cyclophosphamide in Hematologic Malignancies in Adults: Peripheral Blood or Bone Marrow—Review of Published Literature
por: Farhan, Shatha, et al.
Publicado: (2016)

A Prospective Study of an HLA-Haploidentical Peripheral Blood Stem Cell Transplantation Regimen Based on Modification of the Dose of Posttransplant Cyclophosphamide for Poor Prognosis or Refractory Hematological Malignancies
por: Nakamae, Hirohisa, et al.
Publicado: (2022)

A Phase II Trial of Melphalan Based Reduced-Intensity Conditioning for Transplantation of T-Replete HLA-Haploidentical Peripheral Blood Stem Cells with Posttransplant Cyclophosphamide in Patients with Hematologic Malignancies
por: Solh, Melhem M., et al.
Publicado: (2021)

Clinical Utility of the Detection of the Loss of the Mismatched HLA in Relapsed Hematological Patients After Haploidentical Stem Cell Transplantation With High-Dose Cyclophosphamide
por: Muñiz, Paula, et al.
Publicado: (2021)

Loss of the Mismatched Human Leukocyte Antigen Haplotype in Two Acute Myelogenous Leukemia Relapses after Haploidentical Bone Marrow Transplantation with Posttransplantation Cyclophosphamide
por: McCurdy, Shannon R., et al.
Publicado: (2016)

Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMT
por: Saraceni, Francesco, et al.
Publicado: (2023)

A prospective international cooperative information technology platform built using open-source tools for improving the access to and safety of bone marrow transplantation in low- and middle-income countries
por: Agarwal, Rajat Kumar, et al.
Publicado: (2014)

Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era
por: Yeh, Jason, et al.
Publicado: (2021)

Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias
por: Fierro-Pineda, Juan C., et al.
Publicado: (2023)

Introduction to the use of belatacept: a fusion protein for the prevention of posttransplant kidney rejection
por: Ippoliti, Giovanbattista, et al.
Publicado: (2012)

Haploidentical hematopoietic cell transplant recipient presents with late‐onset Epstein Barr virus‐associated posttransplant lymphoproliferative disorder
por: Braun, Adam, et al.
Publicado: (2023)

Dose-adapted post-transplant cyclophosphamide for HLA-haploidentical transplantation in Fanconi anemia
por: Thakar, Monica S., et al.
Publicado: (2017)

Salvage HLA-haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for graft failure in non-malignant disorders
por: Albert, Michael H., et al.
Publicado: (2021)

Efflux capacity and aldehyde dehydrogenase both contribute to CD8(+) T-cell resistance to posttransplant cyclophosphamide
por: Patterson, Michael T., et al.
Publicado: (2022)

Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD
por: Maurer, Katie, et al.
Publicado: (2023)

T cell-depleted hla-haploidentical stem cell transplantation in thalassemia young patients
por: Sodani, Pietro, et al.
Publicado: (2011)

Low-Dose Anti-Thymocyte Globulin Plus Low-Dose Posttransplant Cyclophosphamide as an Effective Regimen for Prophylaxis of Graft Versus Host Disease After Haploidentical Peripheral Blood Stem Cell Transplantation With Maternal/Collateral Related Donors
por: Li, Ting, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r3d1eu1g83u23ua8hto425vh40